Quick Take
Inventiva S.A. (IVA) has filed to raise $90 million in an IPO of its ADSs representing ordinary shares, according to an F-1 registration statement.
The firm is a clinical stage biopharma developing treatments for NASH (non alcoholic steato hepatitis), MPS (mucopolysaccharidoses) and other diseases.
IVA is preparing to enter Phase 3 trials for its lead candidate for the treatment of NASH.
I’ll provide an update when we learn more about the IPO from management.
Company & Technology
Daix, France-based Inventiva was founded to advance a pipeline of treatment candidates for various